相似文献
1
How should we use convalescent plasma therapies for the management of COVID-19?
Blood. 2021 Mar 25;137(12):1573-1581. doi: 10.1182/blood.2020008903.
2
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
3
Convalescent plasma and hyperimmune globulin therapy in COVID-19.
Expert Rev Clin Immunol. 2021 Apr;17(4):309-316. doi: 10.1080/1744666X.2021.1894927. Epub 2021 Mar 12.
4
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
5
Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Transfusion. 2021 Jun;61(6):1705-1709. doi: 10.1111/trf.16378. Epub 2021 Mar 22.
6
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
7
Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
J Infect Dis. 2020 Oct 13;222(10):1620-1628. doi: 10.1093/infdis/jiaa505.
8
Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Trials. 2021 May 17;22(1):342. doi: 10.1186/s13063-021-05189-6.
9
Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.
Pediatr Blood Cancer. 2020 Nov;67(11):e28693. doi: 10.1002/pbc.28693. Epub 2020 Sep 4.
10
Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
BMC Infect Dis. 2022 Jun 27;22(1):575. doi: 10.1186/s12879-022-07560-7.
引用本文的文献
1
The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness.
Front Immunol. 2024 Sep 9;15:1448720. doi: 10.3389/fimmu.2024.1448720. eCollection 2024.
2
The effect of convalescent plasma therapy on the rate of nucleic acid negative conversion in patients with persistent COVID-19 test positivity.
Front Pharmacol. 2024 Aug 1;15:1421516. doi: 10.3389/fphar.2024.1421516. eCollection 2024.
3
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
4
Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review.
Biology (Basel). 2023 Jan 22;12(2):177. doi: 10.3390/biology12020177.
5
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.
Process Biochem. 2023 Apr;127:66-81. doi: 10.1016/j.procbio.2023.01.018. Epub 2023 Jan 31.
6
Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients.
Viruses. 2022 Dec 30;15(1):119. doi: 10.3390/v15010119.
7
Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19.
Clin Immunol. 2022 Nov;244:109093. doi: 10.1016/j.clim.2022.109093. Epub 2022 Aug 6.
8
Lessons from SARS‑CoV‑2 and its variants (Review).
Mol Med Rep. 2022 Aug;26(2). doi: 10.3892/mmr.2022.12779. Epub 2022 Jun 22.
9
Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review.
Transfus Med Hemother. 2022 Mar 23;5(4):1-11. doi: 10.1159/000522264.
10
Convalescent plasma in COVID-19: renewed focus on the timing and effectiveness of an old therapy.
Blood Res. 2022 Mar 31;57(1):6-12. doi: 10.5045/br.2021.2021151.
本文引用的文献
1
Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
Trials. 2021 May 4;22(1):323. doi: 10.1186/s13063-021-05235-3.
2
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
3
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.
4
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
5
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.
Haematologica. 2020 Dec 1;105(12):2834-2840. doi: 10.3324/haematol.2020.261784.
6
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
N Engl J Med. 2021 Feb 18;384(7):619-629. doi: 10.1056/NEJMoa2031304. Epub 2020 Nov 24.
7
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.
8
Convalescent plasma is ineffective for covid-19.
BMJ. 2020 Oct 22;371:m4072. doi: 10.1136/bmj.m4072.
9
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600. doi: 10.1002/14651858.CD013600.pub3.
10
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19.
Cancer Cell. 2020 Nov 9;38(5):661-671.e2. doi: 10.1016/j.ccell.2020.09.007. Epub 2020 Sep 15.
Zotero 插件